Adam Burgoyne, MD, PhD

I am a physician-scientist that joined the Division of Hematology/Oncology at the UC San Diego Moores Cancer Center in February 2017, where I am currently an Assistant Clinical Professor. In my medical oncology clinical practice, I specialize in the treatment of gastrointestinal and hepatobiliary tumors, using traditional chemotherapy, immunotherapy, and targeted therapy, with an emphasis on personalized medicine. My translational and clinical research interests parallel my clinical practice. As a physician-scientist with a background in molecular biology, my primary focus is on the development and characterization of a cellular state prediction model of sensitivity and resistance to novel drugs that inhibit multiple targets within liver cancer cells. This research has been funded by the Food and Drug Administration to support basic science efforts as well as a phase 1 clinical trial of the investigational dual PI3K/BRD4 inhibitor SF1126 in patients with advanced hepatocellular carcinoma. Other research interests include improving the understanding of the tumor genetics and biology of gastrointestinal stromal tumors (GIST) to facilitate the use of precision oncology to personalize care for cancer patients.